| First Author | Sethna S | Year | 2021 |
| Journal | Elife | Volume | 10 |
| PubMed ID | 34751129 | Mgi Jnum | J:342718 |
| Mgi Id | MGI:6810516 | Doi | 10.7554/eLife.67361 |
| Citation | Sethna S, et al. (2021) Proposed therapy, developed in a Pcdh15-deficient mouse, for progressive loss of vision in human Usher syndrome. Elife 10:e67361 |
| abstractText | Usher syndrome type I (USH1) is characterized by deafness, vestibular areflexia, and progressive retinal degeneration. The protein-truncating p.Arg245* founder variant of PCDH15 (USH1F) has an ~2% carrier frequency amongst Ashkenazi Jews accounts for ~60% of their USH1 cases. Here, longitudinal phenotyping in 13 USH1F individuals revealed progressive retinal degeneration, leading to severe vision loss with macular atrophy by the sixth decade. Half of the affected individuals were legally blind by their mid-50s. The mouse Pcdh15(R250X) variant is equivalent to human p.Arg245*. Homozygous Pcdh15(R250X) mice also have visual deficits and aberrant light-dependent translocation of the phototransduction cascade proteins, arrestin, and transducin. Retinal pigment epithelium (RPE)-specific retinoid cycle proteins, RPE65 and CRALBP, were also reduced in Pcdh15(R250X) mice, indicating a dual role for protocadherin-15 in photoreceptors and RPE. Exogenous 9-cis retinal improved ERG amplitudes in Pcdh15(R250X) mice, suggesting a basis for a clinical trial of FDA-approved retinoids to preserve vision in USH1F patients. |
